Abbott Gmbh & Co Kg

Abbvie Deutschland Gmbh and Co Kg

Abbvie Inc.

Abbott Laboratories Corporation

Basf Aktiengesellschaft

Karla Drescher

Andreas Haupt

Liliane Unger

Wilfried Martin Braje

Sean Colm Turner

Karsten M Wicke

Roland Grandel

Hervé Geneste

Michael Ochse

Jürgen Dinges

Clarissa Jakob

Udo Lange

Gisela Backfisch

Ana Lucia Relo

Wilfried Lubisch

Anton Bespalov

Wolfgang Wernet

Helmut Mack

Berthold Behl

Mario Mezler

Margaretha Henrica Maria Bakker

Min Zhang

Loic Laplanche

Matthias Mayrer

Viktor Lakics

Frauke Pohlki

Katja Jantos

Rainer Munschauer

Beate Hellendahl

Ana-Lucia Relo

Siegfried Bialojan

Annegret Lansky

Juergen Delzer

Barbara Vogg

Hannes Koolman

Lawrence A Black

Herve Geneste

Daryl Richard Sauer

Hans-J&uuml;rgen Teschendorf

Christophe Henry

Carolin Hoft

Armin Beyerbach

Robert Van Waterschoot

Martin Winn

Bryan K Sorensen

Vince S Yeh

Jyoti R Patel

James T Link

Hong Yong

Jeffrey J Rohde

Marina Pliushchev

Hwan-soo Jae

Qi Shuai

Dariusz Wodka

Yanbin Lao

David J Madar

Peer Jacobson

Jurgen Dinges

Michael E Brune

Ravi Kurukulasuriya

Jiahong Wang

Lynne E Rueter

Kaitlin E Browman

R Scott Bitner

Günter Blaich

Xiaona Zhao

Raimund Peter

Ana Lucia Jongen-Relo

Thomas Erhard

Anna Linsenmeier

Thomas Subkowski

Dorothea Starck

Hans-Jurgen Teschendorf

Reinhold Mueller

Yixian Chen

Andrea Hager-Wernet, Legal Representative

Jayne Froggett

Alfred Hahn, Legal Representative

Hervë Geneste

Maricel Torrent

Scott Mittelstadt

Yixian Long

Ruxu Xu

Thomas Schultz

Hans-Jürgen Teschendorf

Lynette Smyth

Jincheng Wang

John Darbyshire

Dan Plata

Rolan Grandel

Anna Reingruber

Ana Relo

The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders. 

Inhibitor compounds of phosphodiesterase type 10A

The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HTreceptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HTreceptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HTreceptor.

Tricyclic quinoline and quinoxaline derivatives

The present invention relates to novel carboxamide compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating or controlling medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.  

Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitors

The present invention relates to compound of formula (I) as tricyclic hexahydrodiazepinoquinolines carrying a cyclic substituent, useful for modulating the 5-HTreceptor and preventing and/or treating conditions and disorders that respond to the modulation of the 5-HTreceptor. The present invention also relates to methods for producing compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for preventing or treating conditions and disorders that respond to the modulation of the 5-HTreceptor by administering compounds of formula (1) or pharmaceutical compositions thereof.

Substituted [1,4]diazepino[6,7,1-ij]quinolines as serotonin 5-HT2C receptor modulators

The present invention relates to tricyclic hexahydrodiazepinoquinolines, such as compounds of formula (I), carrying a substituted alkyl radical, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HTreceptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HTreceptor, to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HTreceptor, and processes for preparing such compounds and compositions. 

Hexahydrodiazepinoquinolines carrying a substituted alkyl radical

The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof:  In formula I the variables Het, A, X, Y, Z, R1, R2, R3, R4, R5 and Q are as defined in the claims. The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof.  The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-&#x3b2;-hydroxysteroid dehydrogenase Type 1 enzyme activity.

Treatment of central nervous system disorders

The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula I as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor. In formula I, the variables have the following meanings:

Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor

Growing community of inventors

Ludwigshafen, Germany

Karla Drescher